Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance

References

• Vassilakopoulos TP, Angelopoulou MK. Advanced and relapsed/refractory HHodgkin lymphoma: what has been achieved during the last 50 years. Semin Hematol. 2013;50(1):4–14.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Rosenberg SA, Friedberg JW, et al. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32(3):163–168.
   PubMed Web of Science ®Google Scholar
• Bröckelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood. 2018;131(15):1666–1678.
   PubMed Web of Science ®Google Scholar
• Bröckelmann PJ, Angelopoulou MK, Vassilakopoulos TP. Prognostic factors in Hodgkin lymphoma. Semin Hematol. 2016;53(3):155–164.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Johnson PW. Treatment of advanced-stage Hodgkin lymphoma. Semin Hematol. 2016;53(3):171–179.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017;18(4):454–463.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454–462.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390(10114):2790–2802.
   PubMed Web of Science ®Google Scholar
• Stephens DM, Li H, Schöder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019;134(15):1238–1246.
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202–215.
   PubMed Web of Science ®Google Scholar
• Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401–409.
   PubMed Web of Science ®Google Scholar
• Matzner Y, Konijn AM, Hershko C. Serum ferritin in hematologic malignancies. Am J Hematol. 1980;9(1):13–22.
   PubMed Web of Science ®Google Scholar
• Yildirim R, Gundogdu M, Erdem F, et al. The levels of serum C-reactive protein, beta 2 microglobulin, ferritin, lactate dehydrogenase and some specific proteins in patients with non-Hodgkin’s lymphoma before and after treatment. Eurasian J Med. 2009;41(3):165–168.
   PubMedGoogle Scholar
• Zhang XZ, Su AL, Hu MQ, et al. Elevated serum ferritin levels in patients with hematologic malignancies. Asian Pac J Cancer Prev. 2014;15(15):6099–6101.
   PubMedGoogle Scholar
• Yoh KA, Lee HS, Park LC, et al. The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2014;14(1):43–49.
   PubMed Web of Science ®Google Scholar
• Yamazaki E, Tomita N, Koyama S, et al. Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type. Med Oncol. 2014;31(9):149.
   PubMed Web of Science ®Google Scholar
• Koyama S, Fujisawa S, Watanabe R, et al. Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int Jnl Lab Hem. 2017;39(1):112–117.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Kim T, Jeong JY, et al. Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma. Int J Hematol. 2020;111(4):559–566.
   PubMed Web of Science ®Google Scholar
• Dörner MH, Abel U, Fritze D, et al. Serum ferritin in relation to the course of Hodgkin’s disease. Cancer. 1983;52(12):2308–2312.
   PubMed Web of Science ®Google Scholar
• Bezwoda WR, Derman DP, Bothwell TH, et al. Serum ferritin and Hodgkin’s disease. Scand J Haematol. 1985;35(5):505–510.
   PubMedGoogle Scholar
• Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Gonzalez ME, et al. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy. Leuk Lymphoma. 2015;56(11):3096–3102.
   PubMed Web of Science ®Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31(11):1860–1861.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: cotswolds meeting. J Clin Oncol. 1989;7(11):1630–1636.
   PubMed Web of Science ®Google Scholar
• Angelopoulou MK, Mosa E, Pangalis GA, et al. The significance of PET/CT in the initial staging of Hodgkin lymphoma: experience outside clinical trials. Anticancer Res. 2017;37(10):5727–5236.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin’s lymphoma. Haematologica. 2002;87(7):701–708. discussion 708.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK, et al. Prognostic implication of the absolute lymphocyte to absolute monocyte count ratio in patients with classical hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens. Oncologist. 2016;21(3):343–353.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–1514.
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Li H, Hong F, et al. Evaluation of the international prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015;171(4):530–538.
   PubMed Web of Science ®Google Scholar
• Hayden AR, Lee DG, Villa D, et al. Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma. Br J Haematol. 2020;189(1):122–127.
   PubMed Web of Science ®Google Scholar
• Asimakopoulos JV, Angelopoulou MK, Arapaki MP, et al. Validation of the simplified international prognostic Score3 in a Hellenic cohort of patients with advanced-stage Hodgkin-lymphoma. Br J Haematol. 2020;190(6):e335–e339.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2004;59(3):765–781.
   PubMed Web of Science ®Google Scholar
• Box GEP, Cox DR. An analysis of transformations. J Royal Statistical Soc: Series B (Methodological). 1964;26:211–243.
   Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.
   Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346.
   PubMedGoogle Scholar
• Cox DR. Regression models and life-tables. J Royal Statistical Soc: Series B (Methodological). 1972;34:187–202.
   Web of Science ®Google Scholar
• Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14(15):1707–1723.
   PubMed Web of Science ®Google Scholar
• Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika. 1980;67(1):145–153.
   Web of Science ®Google Scholar
• Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika. 1990;77(1):147–160.
   Web of Science ®Google Scholar
• Royston P, Sauerbrei W. Bootstrap assessment of the stability of multivariable models. Stata J. 2009;9(4):547–570.
   Web of Science ®Google Scholar
• Efron B. Better bootstrap confidence intervals. J Am Stat Assoc. 1987;82(397):171–185.
   Web of Science ®Google Scholar
• Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med. 1996;15(4):361–387.
   PubMed Web of Science ®Google Scholar
• Akaike H. Information theory and an extension of the maximum likelihood principle. In: Parzen E, Tanabe K, Kitagawa G, editors. Selected papers of hirotugu akaike. Springer series in statistics (perspectives in statistics). New York (NY): Springer; 1998. p. 199–213.
   Google Scholar
• André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794.
   PubMed Web of Science ®Google Scholar
• Lopez A, Cacoub P, Macdougall IC, et al. Iron deficiency anaemia. Lancet. 2016;387(10021):907–916.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–254.
   PubMed Web of Science ®Google Scholar
• Killilea DW, Wong SL, Cahaya HS, et al. Iron accumulation during cellular senescence. Ann N Y Acad Sci. 2004;1019:365–367.
   PubMed Web of Science ®Google Scholar
• Hofer T, Marzetti E, Xu J, et al. Increased iron content and RNA oxidative damage in skeletal muscle with aging and disuse atrophy. Exp Gerontol. 2008;43(6):563–570.
   PubMed Web of Science ®Google Scholar
• Picca A, Mankowski RT, Kamenov G, et al. Advanced age is associated with iron dyshomeostasis and mitochondrial DNA damage in human skeletal muscle. Cells. 2019;8(12):1525.
   PubMed Web of Science ®Google Scholar
• Major A, Jackson MW, Smith DE, et al. Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. Leuk Lymphoma. 2019;60(5):1234–1243.
   PubMed Web of Science ®Google Scholar
• Andrews M, Soto N, Arredondo-Olguín M. Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity. Nutrition. 2015;31(1):51–57.
   PubMed Web of Science ®Google Scholar
• Guglielmi V, D’Adamo M, Bellia A, et al. Iron status in obesity: an independent association with metabolic parameters and effect of weight loss. Nutr Metab Cardiovasc Dis. 2015;25(6):541–547.
   PubMed Web of Science ®Google Scholar
• Suárez-Ortegón MF, Ensaldo-Carrasco E, Shi T, et al. Ferritin, metabolic syndrome and its components: a systematic review and meta-analysis. Atherosclerosis. 2018;275:97–106.
   PubMed Web of Science ®Google Scholar
• Khan A, Khan WM, Ayub M, et al. Ferritin is a marker of inflammation rather than iron deficiency in overweight and obese people. J Obes. 2016;2016:1–7.
   Google Scholar
• Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European task force on lymphoma project on lymphocyte-predominant Hodgkin’s disease. J Clin Oncol. 1999;17(3):776–783.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin’s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin’s Study Group trials. J Clin Oncol. 2005;23(24):5739–5745.
   PubMed Web of Science ®Google Scholar
• Herling M, Rassidakis GZ, Medeiros LJ, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res. 2003;9(6):2114–2120.
   PubMed Web of Science ®Google Scholar
• King RL, Howard MT, Bagg A. Hodgkin lymphoma: pathology, pathogenesis, and a plethora of potential prognostic predictors. Adv Anat Pathol. 2014;21(1):12–25.
   PubMed Web of Science ®Google Scholar
• Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma. 2009;9(3):206–216.
   PubMedGoogle Scholar
• Sculier D, Doco-Lecompte T, Rougemont M, et al. Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature. J Int AIDS Soc. 2014;17(4 Suppl 3):19650.
   PubMedGoogle Scholar
• Malkan UY, Gunes G, Aslan T, et al. Common variable immune deficiency associated Hodgkin’s lymphoma complicated with EBV-linked hemophagocytic lymphohistiocytosis: a case report. Int J Clin Exp Med. 2015;8(8):14203–14206.
   PubMed Web of Science ®Google Scholar
• Hyun G, Robbins KJ, Wilgus N, et al. Hemophagocytic lymphohistiocytosis in a patient with classical Hodgkin lymphoma. Case Rep Hematol. 2016;2016:2103612.
   PubMedGoogle Scholar
• Hu S, Bansal P, Lynch D, et al. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature. J Med Case Rep. 2016;10(1):365.
   PubMedGoogle Scholar
• Booth AL, Osehobo P, Rodgers-Soriano D, et al. Hemophagocytic lymphohistiocytosis secondary to unknown underlying Hodgkin lymphoma presenting with a cholestatic pattern of liver injury. Case Rep Gastroenterol. 2018;12(1):99–108.
   PubMedGoogle Scholar
• Knox B, Singh D, Mai H, et al. Hodgkin’s lymphoma with HLH and complete remission with brentuximab-based therapy. BMJ Case Rep. 2019;12(12):e231629.
   PubMedGoogle Scholar
• El-Galaly TC, d’Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508–4514.
   PubMed Web of Science ®Google Scholar
• deAndrés-Galiana EJ, Fernández-Martínez JL, Luaces O, et al. On the prediction of Hodgkin lymphoma treatment response. Clin Transl Oncol. 2015;17(8):612–619.
   PubMed Web of Science ®Google Scholar